SN.
Published date:
Thursday, August 14, 2008Smith & Nephew (SN.) 600.5p.
Shares in the medical technology expert rose 9% last week after robust interim results suggested May's profit warning will soon be a distant memory. Underlying sales growth of 8% means the 18% share price fall after revelations of poor performance from the Plus acquisition was overdone. As economic uncertainty persists, investors should snap up shares in a firm expected to generate 11% earnings per share growth this year and 20% next.
Other stories from : Plays
